HTTR 2024 Highlights

Molecularly targeted drugs are the first choice in the treatment of driver mutation-positive NSCLC patients. However, emergence of acquired resistance is almost inevitable despite dramatic initial response to these drugs. Many basic and translational research are ongoing in this field and new discoveries are reported day by day. The IASLC 2024 HTTR meeting was held to learn about such latest findings, especially focusing on basic and translational perspectives. In this webinar, we will introduce three lectures from the IASLC 2024 HTTR meeting.

Live Activity: February 12, 2025
Enduring Activity Publish Date: March 14, 2025
Enduring Activity Expiration Date: March 13, 2026

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.

Upon completion of this educational activity, participants should be able to:

Outline ongoing clinical trials on combination strategies to prevent or delay the emergence of acquired resistance
Explain the underlying basic/translational mechanisms of TKI resistance
Illustrate the mechanisms of ADC overcoming TKI resistance
Identify SCLC transformation as one of acquired resistances
Explain some potential molecular mechanisms underlying SCLC transformation.

Moderators:

Christian Rolfo, MD, PhD, MBA, Dr.hc. The Arthur G. James Comprehensive Cancer Center, USA
Kenichi Suda, MD, PhD, Kindai Unversity Faculty of Medicine, Osaka, Japan

Presenters:

Lizza Hendricks, MD, Maastricht University Medical Center, Beek, Netherlands
Pasi Janne, MD, PhD, Dana Farber Cancer Institute, Boston, MA, USA
Triparna Sen, MD, Icahn School of Medicine at Mount Sinai, New York, NY, USA

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose:

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Clarissa Baldotto	1.AstraZeneca Brazil, Roche Brazil, MSD Brazil, Janssen LATAM, Takeda, Daiichi Sankyo, Pfizer	1.Speaker	Planner/Reviewer
Lizza Henricks	1.Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Novartis, Gilead 2.AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GSK, Sanofi, Pfizer, Medtalks, Benecke, VJOncology, Medimix 3.Abbvie, Amgen, Anhearth, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Summit Therapeutics, Takeda 4.AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, Abbvie, Gilead, MSD, Merck, Amgen, Boehringer Ingelheim, Pfizer	1.Research Funding 2.Speaker 3.Advisory Board 4.Clinical Trials	Faculty
Hidehito Horinouchi	1.Taiho Pharmaceutical, Merck Serono, Novartis, MSD Oncology, Chugai Pharma, Ono Pharmaceutical, A2 Healthcare, Daiichi Sankyo, BMKK, AbbVie, AstraZeneca 2.Lilly, Bristol-Myers Squibb Japan, Kyowa Kirin, Chugai Pharma, AstraZeneca, MSD Oncology	1.Research Funding 2.Honoraria	Planner/Reviewer
Pasi Janne	1.AstraZeneca, Boehringer Ingelheim, Pfizer, Roche/Genentech, Chugai Pharmaceuticals, Eli Lilly Pharmaceuticals, SFJ Pharmaceuticals, Voronoi, Daiichi-Sakyo, Biocartis, Novartis, Sanofi, Takeda Oncology, Mirati Therapeutics, Transcenta, Silicon Therapeutics, Syndax, Nuvalent, Bayer, Esai, Allorion, Accutar Biotech, AbbVie, Monte Rosa, Scorpion Therapeutics, Merus, Frontier Medicines, Hongyun Biotechnology, Duality Biologics, Blueprint Medicines, Dizal Pharma 2.Gatekeeper Pharmaceuticals 3.AstraZeneca, Daiichi-Sankyo, PUMA, Eli Lilly Pharmaceuticals, Behringer Ingelheim, Revolution Medicines, Takeda Oncology 4.LabCorp	1.Consultant 2.Stock Ownership 3.Research Funding 4.Royalties	Faculty
Christian Rolfo	1.Intellisphere, MedStar, BMS, Novartis, Invitae, EMD Serono, AstraZeneca, Roche, Guardant Health, Pfizer	1.Consultant	Moderator
Triparna Sen	1.Jazz Pharmaceuticals, Debiopharm 2.Regeneron, BMS	1.Research Funding 2.Advisor	Faculty
Kenichi Suda	1.AstraZeneca, Guardant 2.Chugai 3.Chugai, AstraZeneca, Daiichi-Sankyo, MSD, Amgen, Boehringer Ingelheim	1.Research Funding 2.Advisor 3.Speaker	Moderator

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC).

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement:
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the live and enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

Countries that accept ACCME-accredited continuing medical education (CME):

The below list includes countries that accept ACCME-accredited continuing medical education (CME). Please note that some countries that accept ACCME-accredited education do not have specific credit requirements for their physicians.

Antigua & Barbuda
Regulator: Antigua & Barbuda Medical Council

Austria
Regulator: Austrian Academy of Physicians on behalf of the Austrian Medical Chamber

Bahamas
Regulator: Bahamas Medical Council

Belgium
Regulator: Group of Belgian Professional Unions of Specialist Doctors

Bhutan
Regulator: Medical and Health Professional Council, Royal Government of Bhutan

Canada
Regulator: Royal College of Physicians and Surgeons of Canada Maintenance of Certification Program

Croatia
Regulator: Croatian Medical Chamber

Gambia, The
Regulator: The Medical and Dental Council of the Gambia

Germany
Regulator: State Chambers of Physicians in the 16 federal states (only in-person, live events)

India, State of Punjab
Regulator: Punjab Medical Council

Israel
Regulator: Scientific Council, Israeli Medical Association

Jamaica
Regulator: Medical Council of Jamaica

Kuwait
Regulator: Professional Licensing - Ministry of Health

Malawi
Regulator: Medical Council of Malawi

Netherlands, The
Regulator: Royal Dutch Society of the Promotion of Medicine

Oman
Regulator: Oman Medical Specialty Board

Qatar
Regulator: Accreditation Section of the Department of Healthcare Professions of the Qatar Ministry of Public Health

Rwanda
Regulator: Rwanda Medical & Dental Council

Saudi Arabia
Regulator: Saudi Commission for Health Specialties

Singapore
Regulator: Singapore Medical Council

South Africa
Regulator: Health Professions Council of South Africa

Spain
Regulator: Spanish Medical Professional Accreditation Council for CPD/CME

Sri Lanka
Regulator: Sri Lanka Medical Council, Sri Lanka Medical Association, and the Ministry of Health

Sweden
Regulator: Swedish Medical Association

Trinidad & Tobago
Regulator: The Trinidad and Tobago Medical Association

Turkey
Regulator: Turkish Medical Association CME-CPD Accreditation Council

United Arab Emirates, Abu Dhabi
Regulator: Department of Health

United Arab Emirates, Dubai
Regulator: Dubai Health Authority

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.

Study the educational content online or print it out, if applicable.

Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.

Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.